Phytoestrogens are a diverse group of plant-derived compounds structurally or functionally mimicking mammalian oestrogens. A variety of effects, in vitro, in animal models and in humans, have been attributed to these compounds. It is generally not appreciated that many commercial rodent diets are formulated with soy as a source of protein and thus large daily doses of phytoestrogens in the form of isoflavones are delivered to the animals. The content of isoflavones in laboratory diets depends on a number of factors and, therefore, varies considerably, both between different formulations, and also from batch to batch of the same formulation. Dietary isoflavones can influence a number of different endpoints, rendering the dietary levels of such compounds an important experimental factor to consider. The levels of isoflavones in common laboratory diets are reviewed in relation to the dietary levels influencing different endpoints.
Phytoestrogens are a diverse group of plantderived biologically active compounds mimicking structure and/or function of the mammalian steroidal oestrogens. They are found throughout the plant kingdom and include compounds such as the flavones, isoflavones, stilbenes and lignans. Their structural and functional similarity to oestrogens allows interaction with the oestrogen receptors and the elicitation of oestrogenic or antioestrogenic effects (Ososki & Kennelly 2003) .
Many of the commonly used naturalingredient laboratory diets use soy and/ or alfalfa as a source of protein, thereby inadvertently adding phytoestrogens in the form of isoflavones and/or coumestrol, respectively. Frequently, it seems that many scientists are unaware of the fact that most natural-ingredient laboratory diets contain isoflavones. This is manifested in the recurrent use of a phrase like 'a standard rodent chow was used', indicating that the details of the animal diet used was unknown to researchers or they considered them unimportant. It may at times seem strikingly ironic that so much time and effort is devoted to research on synthetic endocrine disrupting chemicals and yet little attention is paid to the inherent endocrine modulation potential of the diet of the animals used in this type of research.
The aim of this paper is to review the isoflavone levels in some of the commonly used laboratory rodent diets. Results from a number of publications that have analysed this will be illustrating the variation in isoflavone levels between different diet brands and batches. As this can be an important variable in several experiments, examples of how animal models can be influenced by dietary isoflavones within the before-mentioned range are also included. This will aid to emphasize the importance of considering animal diet as an essential experimental factor that should be controlled, when attempting to obtain predictable and reproducible animal models and, subsequently, results. Although a multitude of effects by phytoestrogens in various forms, doses, routes of administration and experimental set-ups have been observed in vitro and clinical studies, as well, this review will focus on results from animal research and on the soy isoflavones. The centre of attention will be the range of dietary isoflavones found in natural-ingredient laboratory diets and a selection of examples of the animal models and associated endpoints influenced. For further reading, the reader is referred to some of the comprehensive reviews on this topic, for example Whitten et al. (1995) , Odum et al. (2001) , Lephart et al. (2002) , Whitten et al. (2002) , Yang and Bittner (2002) , Cos et al. (2003) and the Committee on Toxicity of Chemicals in Food, Consumer Products and the Environment (COT) (2003) .
Isoflavones in general
The isoflavones are a subgroup of the flavones, but contrary to the flavones, they have a limited distribution in the plant kingdom (Dixon 2004) , with soybeans essentially being the only commonly consumed plant to hold nutritionally relevant amounts (Ososki & Kennelly 2003) . The isoflavones possess a chemical structure ( Figure 1 ) similar to that of 17-b-oestradiol, which is the most potent naturally occurring oestrogen.
In addition to the structural similarity oestradiol also shares some degree of functional similarity as isoflavones have (a weaker) affinity for the oestrogen receptors. This property enables the isoflavones to elicit oestrogenic or antioestrogenic effects (Dixon 2004) . Compounds that can act as both oestrogen agonists and antagonists are often referred to as 'selective oestrogen receptor modulators', and this property is believed to be responsible for the differential effects of the isoflavones and other phytoestrogens, compared with oestrogens (Cornwell et al. 2004) .
The similarities allow the isoflavones to affect a number of the oestrogen-regulated systems including the reproductive, central nervous, cardiovascular and skeletal systems (Thigpen et al. 2004) .
During recent years, the possible health benefits of dietary phytoestrogens have resulted in a massive scientific attention which is reflected in the growing number of publications within this field. In vivo and in vitro research suggests beneficial effect of the soy isoflavones on, for example, osteoporosis, cancer induction, and development and cardiovascular disease. A quick search of the database 'Pubmed' for the key phrase 'effects of isoflavones' demonstrates this trend as a profound difference in the number of publications between, for instance, years 1990 and 2004, where the former year revealed 58 publications, and the latter 506.
When it comes to the observed effects of isoflavones in a number of animal models and experimental set-ups, it is very important to be aware of, and appreciate, the fact that several of the commonly used laboratory diets are formulated with soy as a source of protein, which at the same time serves as a source of isoflavones in these diets.
In soy, the primary isoflavones are genistein and daidzein in the form of glycosides (Messina et al. 2004) . A sustained high serum concentration of isoflavones is observed in animals fed soy-containing diet formulations (Brown & Setchell 2001) . As these dietary isoflavones can influence a number of oestrogen-regulated systems and processes, they can potentially influence or perturb experimental results if such endpoints are studied. Dietary isoflavones can influence the reproductive, skeletal, central nervous and cardiovascular systems (Thigpen et al. 2004 ) and because of this they can potentially influence and alter experimental results on comparative oestrogenicity, endocrine disruption and carcinogenicity.
To avoid unnecessary concern regarding the effects of this dietary component on experimental results, or just unsatisfactory or unexpected results, the relationship between the isoflavone levels of the different laboratory diets and the threshold level of isoflavones potentially eliciting interference must be considered. Although important, the isoflavone level in the diet is not the only factor to be considered in relation to the effects of experimental results. A number of other experimental variables determine the potency and effects of dietary phytoestrogen exposure. These include:
Timing and duration of exposure; shortterm vs. long-term, during gestation, growth or maturity. The dose of phytoestrogen; the animal model utilized, i.e. species, strain/stock and sex.
The endpoints monitored; how sensitive are they to oestrogenic and antioestrogenic actions.
This number of confounding factors makes it difficult to predict the exact effects of any phytoestrogen exposure, and may lead to apparently conflicting results.
Isoflavones in laboratory rodent diets
A number of studies have determined the isoflavone content in different laboratory rodent diets. The content of isoflavones in laboratory diets depends on a number of factors, the soy content of the diet being the obvious one. However, the isoflavone content of soy beans can vary, in some cases several fold (Wang & Murphy 1994) . The isoflavone content of soy depends on soy variety and growth conditions, such as soil quality, temperature, humidity season and length of day (Eldridge & Kwolek 1983 , Wang & Murphy 1994 . These factors help explain both the difference between different diet brands, and the large batch-to-batch variation in the diet formulations. The lack of a standardized method of analysis may be an additional confounding factor.
The isoflavone ranges of a number of commonly used laboratory rodent diets observed in different publications, are illustrated in Figure 2 (Thigpen et al. 1999 , Degen et al. 2002 , Owens et al. 2003 .
Animal models impacted by dietary isoflavones
The steroidal oestrogens are involved in the growth and function of female and male reproductive tissues, maintenance of the skeletal and central nervous system (CNS) and protection of the cardiovascular system (Gruber et al. 2002) . As the isoflavones potentially influence all such oestrogenregulated pathways and systems, dietary intake may have profound physiological impact. The following sections will review research on animal models and the effects of dietary isoflavones in relevant doses, i.e. in a range similar to those found in naturalingredient laboratory diets. Results are summarized according to physiological system and/or endpoints studied. As soy is one of the main source of phytoestrogenic compounds in most laboratory diets, the focus will be on the soy phytoestrogens, i.e. the isoflavones genistein and daidzein.
Animal models involving the reproductive system
Inconsistent results make it difficult to draw definite conclusions on appropriate dietary Laboratory Animals (2007) 41 levels of isoflavones for studies of the female reproductive system.
However, when dealing with models used in endocrine disrupter studies such as the uterotrophic assay, numerous scientists have urged for caution and recommended paying attention to isoflavones in the diet (Kanno et al. 2002 , Thigpen et al. 2002 , Colborn 2004 , Stokes 2004 . The rodent uterotrophic bioassay is used in the determination of oestrogenic or antioestrogenic potential of chemical compounds. In the identification and assessment of the reproductive hazard of endocrine disrupters, the suspected oestrogenic compounds are tested for their ability to elicit uterotrophic growth in immature or ovariectomized rodents (Thigpen et al. 2002 , Cornwell et al. 2004 . A number of studies, using the uterotrophic assay, in which dietary soy/isoflavones is a factor, are described in the following section and summarized in Table 1.
In the often-cited publication by Boettger-Tong et al. (1998) , it was observed that an established, previously well-functioning model for the uterotrophic assay suddenly failed to respond to the administration of exogenous oestrogen. Immature 20-21-dayold rats were purchased and the experimental treatments were started about one week later. It was observed that test animals did not respond to exogenous oestrogen administration and no difference in uterus weight between test and control animals was found. They later established the isoflavone content of the diet of the animal supplier to be responsible for the observed phenomenon. The diet used by the animal supplier was a natural-ingredient variety with isoflavone content in the range of 350 mg/g diet. They found that the lack of uterotrophic response to experimental oestrogen administration was caused by the increased uterine weights of the control rats. These rats already exhibited a maximal uterotrophic response due to the isoflavones in the diet, thus rendering further stimulation and subsequent response impossible.
In a similar experimental regime by Wade et al. (2003) , rats were exposed to dietary isoflavones in levels of 35, 75, 235 or 1050 mg/g diet in utero and through day 21. However, in this case, only a minor decrease in assay sensitivity was observed in the group fed the highest isoflavone levels (Wade et al. 2003) . The uterine weights of the rats fed 1000 mg/g isoflavones was increased above that of the control animals, thereby slightly reducing assay sensitivity. The overall conclusion of the study was that perinatal and developmental exposure to dietary isoflavones does not affect later responsiveness of the uterotrophic assay to exogenous oestrogen administration. However, high levels of dietary isoflavones (1000 mg/g) can influence assay sensitivity through a reduction of threshold level and dynamic response range.
Results from a study by Yamasaki et al. (2002) illustrates that experimental design is of great importance, when evaluating effects of dietary isoflavones on the uterotrophic assay. In this study, a shorter exposure (13 days) of young animals to dietary isoflavones in the concentrations ranging from 30 to 150 and 300 mg/g diet had no influence on the outcome of the uterotrophic assay. The uterotrophic response was similar irrespective of diet, both when testing potent oestrogens, as 17-aethinyloestradiol (EE), or weaker oestrogenic substances, as bisphenol A.
Studies by Degen et al. (2002) and Ashby et al. (2000) suggest that dietary phytoestrogen is not the only factor to consider when attempting to optimize the uterotrophic assay. This is illustrated by the observations made, where the former found a reduction in assay sensitivity to exogenous oestrogen administration in animals fed a diet completely devoid of phytoestrogens, and the latter that the control uterine weights of animals fed phytoestrogen-free diets were increased, thus also reducing assay sensitivity. These results suggest that a diet's potential oestrogenicity, as determined by its ability to induce uterine (2002) growth, cannot be based on the isoflavone content alone (Ashby et al. 2000 , Degen et al. 2002 . The effects of diet on rodent sexual development are also described in a comprehensive paper by Odum et al. (2001) .
Models of the male reproductive system can also be influenced by dietary isoflavones. Endpoints such as reproductive organ weights, hormone levels and anogenital distance are often used to assess effects on the reproductive system and may be sensitive to the hormonal mimicry/activity of the phytoestrogens. The male equivalent to the uterotrophic assay, the Hershberger assay, is used to assess the androgenic or antiandrogenic potential of chemical compounds via the effects on the growth of the male accessory sex organs (Stroheker et al. 2003) . Studies on male reproductive parameters that have been influenced by dietary soy isoflavones are described and summarized in Table 2 .
In Weber et al. (2001) the effects of a shortterm feeding with a diet rich in isoflavones on several male reproductive parameters were investigated. Male rats were divided into two groups and fed either a diet free of phytoestrogens or a diet with an isoflavone level of 600 mg/g diet. Following five weeks of feeding, animals were euthanized, reproductive organs weighed and hormone assays performed. It was observed that animals fed a diet rich in isoflavones had significantly lower prostate weights compared with animals fed an isoflavonefree diet. Moreover, the serum levels of testosterone and androstenedione were also significantly lower in animals fed isoflavones at 600 mg/g diet. Stroheker et al. (2003) found dietary isoflavones to have an impact on the sensitivity of the Hershberger assay. Male rats were bred on different diets containing isoflavones at levels of 0, 620 or 920 mg/g diet. The Hershberger assay was performed from day 28 to day 38; groups of animals were exposed to androgenic and antiandrogenic compounds, and accessory sex organ weights were recorded. Animals fed on an isoflavone-rich diet had a significantly reduced response to androgen administration, (2003) i.e. smaller organs, whereas the response to antiandrogens was similar in all diet groups. The overall conclusion of the study was that careful consideration of the diet used in endocrine studies should be made, and a diet devoid of phytoestrogens is preferable when the Hershberger assay is performed. Wisniewski et al. (2003) investigated the effects of lifelong dietary genistein exposure on reproductive organs and hormone levels. Male rats were bred on soy-free diets supplemented with genistein at levels of 0, 5 or 300 mg/g diet. On days 2 through 21, anogenital distance was measured; on days 40-45, testis size was measured; and in the adult animals, reproductive organ weights were measured and hormone assays performed. It was observed that the anogenital distance in the immature animals was significantly reduced in males fed a diet with 300 mg isoflavones/g diet as compared with males fed a diet free of isoflavones. By puberty (days 40-45) the testis size was also significantly smaller in males fed the isoflavone diet. By adulthood, the size of epididymis and prostate was significantly reduced in males fed isoflavones, as were the serum testosterone levels. The overall conclusion of this study was that gestational and lactational exposure to dietary genistein leads to alterations in the development of male genitalia.
The impact of dietary phytoestrogens on the outcome of the uterotrophic assay and on the development of male reproductive organs has yielded conflicting results. Many scientists, therefore, strongly recommend that attention must be paid to the phytoestrogen content of animal diets, and the use of diet with high levels of phytoestrogens should be avoided for studies of hormone-sensitive endpoints (Thigpen et al. 1999 , Degen et al. 2002 , Owens et al. 2003 . Diets formulated without soy and thus containing negligible amounts of isoflavones are commercially available ( Figure 2) and can be considered, as can the purified diets.
Animal models of the skeletal system It has been demonstrated that soy isoflavones have beneficial bone-sparing effects in both postmenopausal women (Yu-Ming et al. 2003 , Messina et al. 2004 ) and in the corresponding animal model, i.e. the ovariectomized rodent (see for example: Arjmandi et al. 1996 , 1998a ,b, Picherit et al. 2000 . The effects of soy isoflavones on skeletal tissue in experimental animals have been highly consistent. A large number of studies have established the bone-sparing effects of dietary soy isoflavones in animal models of osteoporosis. Several of these studies involving dietary soy or soy isoflavones are described, and summarized in Table 3 . Arjmandi et al. (1996) conducted a study with the purpose of determining whether soy bean protein isolate prevents bone loss induced by the ovarian hormone deficiency created by ovariectomy (OVX). Four groups of female rats were used. Rats in three of the groups were ovariectomized (OVX) and one was sham-operated. Of the three OVX groups, one was fed on a casein-based diet, one on a soy-based diet, and one on a caseinbased diet, together with subcutaneous 17-boestradiol administration. The shamoperated group was fed on the casein-based diet. The two diets differed in protein source, but were otherwise comparable. Based on the amount of added soy protein isolate and the isoflavone content in the isolate stated in the authors' subsequent articles, the isoflavone content of the soy diet was approximately 440 mg/g. Bone mineral density (BMD) was measured in the femur and the fourth lumbar vertebra. After 30 days, it was observed that OVX induced a significant loss of BMD; however this was prevented in animals administered 17-boestradiol. The soy-based diet prevented bone loss in the lumbar vertebra and reduced that in the femur, which implied that the soy-based diet was more effective in preventing trabecular bone loss than cortical bone loss. Authors agree that since trabecular bone is more readily lost in the OVX model, it would be reasonable to assume that this type of bone will be correspondingly more responsive to soy treatment than cortical bone.
In a subsequent study, Arjmandi et al. (1998b) 
bone-sparing effects of soy is due to the isoflavone content. Four groups of female rats were used, one sham-operated group fed a casein-based diet, one OVX group fed a casein-based diet, one OVX group fed a soybased diet with normal isoflavone content and one OVX group fed a soy-based diet with reduced isoflavone content. The isoflavone content of the soy diets was approximately 440 and 44 mg/g, respectively. The diets differed in the source of protein and isoflavone levels but were otherwise isoenergetic and comparable. BMD was measured in the femur. During the 35 days experimental period, the OVX groups fed casein diet and reduced isoflavone diet experienced an approximate 5% reduction in femur BMD compared with the shamoperated animals. This significant reduction in BMD was prevented in the animals fed a diet with 440 mg isoflavones/g. Serum markers of bone turnover showed a similar increased turnover in all OVX groups. The authors suggest that this pattern of sustained BMD in spite of increased turnover reflects a pattern of formation exceeding absorption, perhaps due to an increased intestinal calcium absorption in the soy-fed animals. Arjmandi et al. (1998a) investigated the effects of dietary soy on already-established bone loss to examine the mechanism behind its bone-sparing effects. Six groups of female rats were used, two sham-operated groups and four ovariectomized groups. After surgery, all groups were fed a casein-based diet for 35 days, when one sham-operated group and one OXV group of rats were euthanized to confirm that bone loss indeed had occurred in the OVX animals. Thereafter the remaining sham-operated rats and one OVX group were fed the casein-based diet and the remaining two OVX groups were fed either a soy-based diet with a normal isoflavone content (approximately 440 mg/g diet) or a soy-based diet with a reduced isoflavone content (approximately 44 mg/g diet). BMD was measured in the femur and in the fourth lumbar vertebra after an additional 65 days of feeding. The OVX positive controls had a significantly lower BMD than sham-operated animals. The femoral density of the soy-fed groups was not significantly different from the OVX positive control animals or the sham-operated animals, thus suggesting a slight reversal of bone loss. The overall conclusion of the study was that dietary soy isoflavones were only slightly effective in reversing femoral, but not lumbar vertebra, bone loss. Picherit et al. (2000) investigated the ability of the soy isoflavones, genistein and daidzein, to prevent OVX-induced bone loss. Five groups of female rats were used, one sham-operated group and four OVX groups that were fed a diet supplemented with either 1000 mg genistein/100 g body weight/ day, 1000 mg daidzein/100 g body weight/ day, 30 mg EE/kg body weight/day or no supplement. These doses of genistein and daidzein could correspond roughly to a diet containing approximately 200 mg isoflavones/ g diet. The supplements were mixed in a soyfree semipurified diet, and this diet was also used for the sham-operated groups and OVX control groups. Following 90 days of feeding, BMD was measured in two regions of the femur and in the second, third, fourth and fifth lumbar vertebra. Both bone regions had a significantly lower BMD in OVX control animals compared with sham-operated animals. Animals fed daidzein or EE had BMDs in all regions similar to shamoperated animals, and in animals fed genistein only one bone region exhibited values similar to those of the sham-operated animals. Bone turnover was increased in control OVX, but was not altered in animals fed daidzein, genistein or EE. The overall conclusion of the study was that daidzein administration of 1000 mg/100 g body weight/ day was efficient in preventing OVX-induced bone loss, a similar genistein dose was not equally effective (Picherit et al. 2000) .
In their subsequent study, Picherit et al. (2001) sought to elucidate if any dosedependent bone-sparing effects of soy isoflavones could be observed.
Five groups of female rats were used, one sham operated and four ovariectomized. The OVX rats were fed an isoflavone supplement in doses of 0, 2000, 4000 or 8000 mg/100 g body weight/day. These doses of isoflavones could correspond roughly to diets containing approximately 0, 300, 600
Laboratory Animals (2007) 41 and 1200 mg isoflavones/g diet. The isoflavones were mixed into the diet which was a soy-free semi-purified diet, which was also fed to the sham-operated group. Following 90 days of feeding, BMD was measured in the femur, both in total and in the diaphyseal and metaphyseal subregions. It was observed that total femur BMD in animals fed isoflavones (all doses) was significantly higher than in OVX controls and similar to values of the sham group. The same observation was made for the diaphyseal BMD for the rats fed isoflavones at doses of 2000 and 4000 mg/100 g body weight/day. The BMD of animals fed 8000 mg/100 g body weight/day was similar to both sham and OVX controls. Metaphyseal BMD was higher in isoflavone groups 4000 and 8000 mg/100 g body weight/day compared with OVX controls and similar to sham animals. In relation to the dose-dependent bone-sparing effect of soy isoflavones, cortical bone exhibited a greater response than callous bone as a diaphyseal BMD absorption was prevented by the lowest isoflavone doses whereas 4000 or 8000 mg/100 g body weight/ day was needed to protect and maintain the metaphyseal BMD. Chanteranne et al. (2002) evaluated a mixture of soy isoflavones genistein and daidzein for its potential bone-sparing effects in the OVX rat. Five groups of female rats were used, sham-operated or OVX rats fed isoflavones in doses of 0, 400, 800 or 1600 mg/ 100 g body weight/day. These doses of isoflavones could correspond roughly (400 g rat eating approximately 20 g diet) to diets containing approximately 0, 100, 150 and 300 mg isoflavones/g diet. Isoflavones were added to the diet in the form of a mixture of pure genistein and daidzein in proportions of 1 genistein to 1.25 daidzein which is the ratio found in soybeans. The diet that was also used for the sham-operated group in an unsupplemented form was a soy-free semipurified variety. Following 90 days of feeding, BMD was measured in the femur. In the group fed isoflavones in the concentration of 1600 mg/100 g body weight/ day, OVX-induced bone loss was prevented. Blum et al. (2003) investigated the effects of a soy-based diet on bone loss induced by OVX. Forty-two female, 11-month-old Sprague-Dawley rats were randomly assigned to one of five groups: an intact control group; two sham-operated groups fed on either casein-or soy-based diets, and two OVX groups fed on either a casein-or soybased diet. The protein content and all other ingredients of the two diets were similar. The isoflavone content of the soy-based diet was 450 mg/g. Following 98 days of feeding, BMD was measured in the femur and in the humerus. The BMD in both regions was greater in OVX rats fed soy-based diet compared with OVX rats fed casein-based diet, but not in a level similar to the shamoperated group. The overall conclusion of the study was that a soy-based diet afforded some preservation of BMD in OVX-induced bone loss, but not a complete maintenance.
The results thus described clearly illustrate that the soy and isoflavone content of laboratory animal diets is an important experimental factor to consider when attempting to achieve consistent and reproducible bone loss. Many commonly used laboratory diets have isoflavone levels that will influence bone loss, i.e. in levels in the range of 300 mg/g and above, rendering them less suitable for such experiments.
Animal models of the CNS
Animal models of the CNS can also potentially be influenced by dietary isoflavones, as oestrogen receptors are also expressed in the CNS. The isoflavones binding to the oestrogen receptors also enable an influence of this physiological system and thus are of interest in studies of potential alterations of behaviour, stress and brain biochemistry.
Results from a selection of studies on anxiety, stress and pain parameters are described and summarized in Tables 4 and 5. In rodents, anxiety-related behaviours are tested and quantified in the elevated plus maze test, which measures the conflict between exploration of the open arm and the security of the closed arm (Lephart et al. 2004) (Lund & Lephart 2001) . Animal models of pain can be either of short term or of chronic pain, e.g. the hot plate tests and the infliction of nerve injury. When rats are placed on a hot plate and exposed to thermal stimuli the time is measured until hindpaw licking occurs. In the chronic model, partial nerve injury is inflicted, and neuropathic pain is measured through mechanical and thermal stimuli. The behavioural tests of stress, anxiety and pain are often used in drug response research. If baseline levels of behaviour are altered because of dietary isoflavones, profound impacts on results, and conclusions would occur. Lund and Lephart (2001) investigated whether exposure to dietary isoflavones in utero and into adulthood had an impact on tests of anxiety. Long-Evans rats were bred on either an isoflavone-free diet or a diet containing 600 mg/g diet. Experimental animals were divided into groups based on gender and maternal diet, i.e. males-fed isoflavone-free diet, males-fed isoflavones at concentrations of 600 mg/g diet and so on. Rats were tested in the elevated plus maze behavioural test. It was observed that both male and female rats fed the diet with 600 mg isoflavones/g diet made significantly more entries onto and spent significantly more time on the open arm of the maze than did animals fed the isoflavone-free diet. The conclusion of the study was that rats fed lifelong with a diet rich in soy isoflavones displayed a marked reduction in anxiety behaviour compared with animals fed a diet free from isoflavones. Lephart et al. (2003) investigated whether dietary soy isoflavones influenced behavioural pain response and levels of stress hormones. Long-Evans rats were bred on an isoflavone-free diet or a diet containing 600 mg/g diet. Males were divided into two diet groups based on maternal diet; one fed a diet free from isoflavones and one with isoflavone levels of 600 mg/g diet. Feeding continued until the animals were 120 days old. Rats were then tested in two stress protocols, the hot plate test and the Plexiglass tube. In the hot plate test, rats were placed on a 501C plate and latency until hindpaw licking was recorded. In the Plexiglass test, rats were subjected to restraint, illumination and heat stress. Thereafter animals were euthanized and blood was collected for hormone assays of adenocorticoid thyroid hormone (ACTH) and corticosterone. In the hot plate test no significant difference between diet groups was observed. In the Plexiglass tube test, the serum levels of corticosterone did not differ significantly between diet groups. However, the serum levels of ACTH were significantly greater in animals fed the 600 mg isoflavones/ g diet compared with the animals fed the isoflavone-free diet. Brain receptor analysis demonstrated that animals fed a diet rich in isoflavones had increased levels of the receptors regulating the ACTH feedback, thus suggesting that brain biochemistry is also influenced by dietary isoflavones. The modification in receptor levels in the animals fed an isoflavone-rich diet altered their stress response to a female-like pattern of higher ACTH release following activation of the stress axis. Hartley et al. (2003) sought to determine if behaviour in tests of anxiety and stress hormone levels were different in animals fed an isoflavone-free diet as compared with animals fed isoflavones at a level of 150 mg/g diet. Male rats were divided into two groups and fed one of the two diets. Following 18 days of feeding, rats were subjected to the social interactions test, in which the amount of time spent in social interaction is taken as a measure of anxiety, i.e. anxiety leading to less time spent in social interactions. Subsequent to the test, half of the rats were subjected to the elevated plus maze test, half were returned to their home cage to be used for measurements of basal hormone levels. It was observed that rats fed the diet with 150 mg isoflavones/g diet spent significantly less time in social interactions than did rats fed the isoflavone-free diet. This anxiogenic effect of dietary isoflavones were repeated in the elevated plus maze test, where significantly fewer entries were made onto and less time was spent on the open arm of the maze. In the hormone assay, it was observed that baseline levels of corticosterone were similar in both diet groups. However, the stress-induced levels were significantly greater in rats fed isoflavones. The overall conclusion of the study was that a diet with a level of 150 mg isoflavones/g diet fed short term was associated with increased anxiogenic response compared with feeding with an isoflavone-free diet. Lephart et al. (2004) investigated whether long-term exposure to dietary isoflavones in young animals influenced tests of anxiety. Male and female Long-Evans rats were fed different diets from day 50 and until day 300. Diets were either free of isoflavones or with levels of 200 or 600 mg/g. Following 250 days of feeding, rats were tested in the elevated plus maze test of anxiety. It was observed that rats fed the isoflavone-containing diets appeared to be less anxious than the rats fed the isoflavone-free diet, as the former spent more time on and made more entries onto the open arm of the maze.
Studies also suggest that dietary phytoestrogens can influence certain pain models. Animal models of neuropathic pain have been developed to study nerve injury. In the partial sciatic ligation (PSL) rat model, the sciatic nerve is ligated producing a model expressing signs of spontaneous pain, allodynia and hyperalgesia in the partially denervated foot. Shir et al. (1998) reported successful use of this model in the period 1986-90, observing consistent sensory disorders. Following this period of success, difficulties in replication of the model was observed; as it was the case with other research groups. In an attempt to elucidate the variables affecting the functionality of the model, they found dietary soy to be important. Shir et al. (1998) subjected several strains of rats (Wistar, Sabra, Sprague-Dawley and Long-Evans) to nerve ligation and responses to sensory stimuli were examined and compared in groups receiving different diets. Diets with soy contents of 20%, 9% and 6%, respectively, were tested for their ability to influence and potentially weaken the PSL model. It was observed that higher soy content in the diet was associated with weaker pain responses. Following this observation, two diets only differing in protein source were tested: one contained 20% soy and one contained 20% casein. Diets were otherwise identical. Animals (gender not stated in article) fed the caseinbased diet developed into a robust PSL model displaying allodynia and hyperalgesia, whereas these responses were significantly ameliorated in animals fed the soy-based diet. The overall conclusion of the study was that dietary soy was one of the factors influencing the PSL pain model and preventing the development of a robust model. Shir et al. (2001) subsequently sought to further clarify the suppressive effects of dietary soy on neuropathic sensory disorders in the PSL pain model. Seven groups of male rats were fed a soy-based diet from weaning and until various points prior to surgery. At all time points (14 days, 7 days, 15 or 0 h) rats were switched to a soy-free casein-based diet. Following nerve ligation, rats were fed either soy-based or casein-based diet. This elaborate experimental regime was to determine whether the pain suppressive effects of dietary soy were due to preoperative or postoperative intake. Allodynia and hyperalgesia were determined preoperatively and on days 3, 8 and 14 postoperatively. It was observed that a preoperative consumption of soy-based diet was associated with suppression of neuropathic pain responses. Consumption of soy both prior to and following surgery was not associated with further amelioration. When soy diet was replaced with casein diet 15 h or more before surgery, the pain suppressive effects was prevented, indicating that the effects were fairly short lived.
Later Shir et al. (2002) sought to determine if the inhibitory effect of soy on pain was mediated through isoflavones. Groups of rats were fed diets with varying levels of soy isoflavones two weeks prior to and two weeks after nerve ligation. Diets had isoflavone levels of 8, 14, 70, 100 and 180 mg/ g diet. Rats fed soy-free diet developed tactile and heat allodynia as well as mechanical hyperalgesia. Rats fed diets formulated with Laboratory Animals (2007) 41 soy did not develop either tactile or heat allodynia. Intermediate levels of isoflavones in plasma were associated with some degree of prevention of allodynia. The overall conclusion was that some of the pain-suppressive properties of dietary soy in the model could be attributed to the phytoestrogens.
These results illustrate that in certain models of the CNS on stress, anxiety and pain, the soy and isoflavone content of the animal diet can be an important variable. The significant difference in response caused by dietary soy may have a profound impact in several studies, as the baseline level of response in behavioural tests has great influence on the evaluation of the drug response (Hartley et al. 2003) .
Animal models of cancer induction and development
The notion that dietary phytoestrogens have a beneficial effect on cancer arise from the observation that several forms of cancer, such as breast, prostate and colon cancer, have a relatively low incidence in Asian countries as compared with Western countries, a tendency that has been attributed to differences in dietary habits. In Asian countries soy and soy foods account for a large part of the diet and because soy beans contain a number of anticarcinogenic substances, a role of soy in cancer prevention has been suggested (Messina et al. 1994) .
A large number of animal studies have investigated the effects of various soy food preparations, including beans, paste and sauce, in various forms of experimental cancer induction and development (see for example Hawrylewicz et al. 1995 and Messina et al. 1994 ). In the review by Messina et al. (1994) , 26 such studies were reviewed and in more than 60% of these (17 out of 26), a protective effect of soy intake on cancer was found. None of the studies revealed negative effects of soy intake. Studies with soy and/or isoflavones in preparations similar to those found in soybased laboratory diets, are described, and summarized in Table 6. A number of constituents have been suggested to be responsible for the beneficial effects of dietary soy on cancer. The general agreement is that the isoflavones are the most active anticancer components in soy but protease inhibitors, phenolic compounds and deficiency in the amino acid methionine may also have roles (Messina et al. 1994 , Hawrylewicz et al. 1995 .
In Barnes et al. (1990) , the effects of two forms dietary soy on two different rodent models of mammary cancer were investigated. In the first model, mammary cancer induction was accomplished by direct acting carcinogen N-methyl-N-nirtosurea (MNU), and soy was fed to the animals in the form of soy bean chips. Soy-free AIN 76A was used as standard control diet. In the test groups, the casein in the control diet was replaced with soy protein. In this model, protein replacement was with 5%, 10% or 20% soy chips and they corresponded to isoflavone levels of 100, 200 and 480. Groups of female rats were fed the different diets from the age of 25 days and injected with carcinogen on day 50 and checked for tumours from day 78. In rats fed diets with soy chips a reduction in the appearance of histologically confirmed tumours was observed. Moreover, the number of tumours per rat was decreased, and tumour latency time was increased.
In the second model, mammary cancer was induced by 3,2-dimethyl-4-aminobiphenyl (DMBA), which requires metabolic activation. Soy was fed to the rats in the form of soy protein isolate replacing casein in the AIN 76A control diet. Protein replacement was 10% and 20% and they corresponded to isoflavone levels of 50 and 100 mg/g diet. Again groups of female rats were fed the different diets from the age of 25 days and injected with carcinogen on day 50 and checked for tumours from day 78. In the rats fed soy protein isolate, a reduction in the number of tumours per rat was observed. Jin and MacDonald (2002) investigated whether dietary isoflavones had an effect on spontaneous mammary tumour development in a transgenic mouse model (MMTV-neu/ErbB-2). This mouse model developed mammary tumours with a long latency period. Four groups of female mice were fed different diets, one casein control, one supplemented with genistein at 250 mg/g diet, one supplemented with daidzein at 250 mg/g diet and one supplemented with a mixture of the two isoflavones at 250 mg/g diet. Mice were fed the experimental diets from 7 to 33 weeks of age. Mice were checked for palpable tumours from the age of three months. The development of tumours differed significantly between diet groups as they appeared in week 23 in control animals fed casein diet as compared with the groups fed isoflavones at week 27. At the end of the study the diet groups did not differ significantly with respect to percentage of mice with tumours, tumour size or tumour numbers. The overall conclusion of the study was that dietary isoflavones in levels of 250 mg/g diet produced a statistically significant and physiologically relevant delay in tumour development.
A number of confounding factors determine the effects of dietary isoflavones. Therefore experimental results can be conflicting, further illustrated by the following study.
In the study by Allred et al. (2004) , an ovariectomized rodent model of mammary cancer was used to study the effects of dietary genistein on previously developed tumours. Female rats were treated with carcinogen on day 21. When tumours had developed, animals were ovariectomized and placed in one of three groups, one fed a casein-based diet and administered oestradiol (positive control), one fed a diet supplemented with genistein at a level of 750 mg/g diet and one fed a casein-based diet (negative control). As mammary tumours are hormone (oestrogen) dependent, the OVX caused tumours to regress. This regression was observed in the animals fed the caseinbased diet only, but was prevented in the groups given either oestradiol or dietary genistein. Dietary genistein produced significantly larger tumours as compared with the negative controls suggesting that genistein prevented tumour regression and also stimulated tumour growth. The results of this study clearly underscore the importance of considering the animal model, the timing of isoflavone exposure and the (2004) endogenous hormone environment before speculating as to the possible effects of dietary isoflavones.
In the male models of hormone-dependent cancers, extensive research has been devoted to prostate cancer. Kato et al. (2000) investigated the effects of dietary genistein and daidzein on prostate cancer induction. In groups of male rats, prostate cancer was induced via injection with the carcinogen DMBA. Dietary isoflavones were administered in the diet in levels of 1000 mg/g diet of genistein or daidzein, and controls were fed an unsupplemented diet. Positive controls were administered testosterone and negative controls were injected with corn oil instead of carcinogen. Animals fed dietary isoflavones had a significantly lower number of ventral prostate carcinomas as compared with animals fed the unsupplemented diet.
In the study by Hikosaka et al. (2004) , the effects of dietary soy isoflavones in another model of prostate cancer were investigated. Groups of male rats were administered the carcinogen 2-amino-1-methyl-6-phenylimidazo-pyridine (PhIP) which was mixed with corn oil. Rats were fed either a soy-free diet or the same diet supplemented with an isoflavone extract, corresponding to a level of 1000 of genistein and daidzein mg/g diet. At the age of 66 weeks animals were euthanized, and histological tumour examinations were performed. The percentage of non-invasive carcinomas in the ventral lobe of the prostate differed significantly between diet groups. In the group fed soy and isoflavone-free diet, 60% of rats developed tumours as compared with only 20% of rats in the group fed the isoflavonesupplemented diet. The overall conclusion was that dietary soy isoflavones produced a significant inhibitory effect on the development of rat prostate carcinogenesis.
Conclusion
Many of the commonly used naturalingredient laboratory animal diets contain soy as a source of protein and, thereby, adding isoflavones to the diets. The isoflavone levels in these diets vary from formulation to formulation, and also from batch to batch in the same formulation. In some instances, this variation can be several fold.
The oestrogen-modulating properties of isoflavones enable potential interference with experimental results in a number of studies utilizing oestrogen-sensitive endpoints. A number of endpoints are influenced by isoflavone levels similar to those found in certain soy-containing diets, thus making it an important confounding, and potentially disrupting, factor.
The soy isoflavone levels of laboratory diets can be an important source of variability between studies, both within and between laboratories. As reproducible and reliable animal models are key factors in high-quality science, awareness and subsequent control of the threshold level which influence experimental results will lead to a better standardization and, thus, better and more reproducible models and results. This will then lead to a reduction in the number of animals necessary to obtain statistically valid results. It is, therefore, of the utmost importance to be aware of the soy and isoflavone content in the diet of the experimental animals, and to know the expected levels of soy isoflavones. It is very difficult to recommend a level of isoflavones that is 'safe', when attempting to minimize interference with experimental results, as it depends on a number of factors. In many of the endpoints and studies reviewed in this communication, the threshold level seems to be in a range 300-400 mg/g diet, in some studies it is more and in others, less. This paper is meant as a word of caution and a reminder to pay attention to laboratory animal diet as an important experimental factor. It is not a recommendation to completely avoid diets containing soy, but standardization of diets with respect to isoflavones would aid research by minimizing variables and maximizing the possibility of replication of research findings. For certain types of experiments, an isoflavone-free or isoflavone-low diet may be considered prudent and as noted in Figure 2 , naturalingredient rodent diets that do not contain soy are commercially available.
